Sinopharm Tech Holdings Limited
國藥科技股份有限公司

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 8156)

PROFIT ALERT
SUBSTANTIAL REDUCTION IN LOSS

This announcement is made by Sinopharm Tech Holdings Limited (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Rule 17.10 of the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited (the "**GEM Listing Rules**") and the Inside Information Provisions (as defined under the GEM Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

The board (the "**Board**") of directors (the "**Director(s)**") of the Company is pleased to inform the shareholders and potential investors of the Company that, based on the preliminary assessment of the unaudited consolidated financial statements of the Group for the year ended 30 June 2025 (the "**Reporting Period**") and the information currently available to the Board, the Group is expected to record a loss attributable to owners of the Company of not more than HK$1 million for the Reporting Period, representing a significant decrease of approximately 95% as compared with the loss attributable to owners of the Company of approximately HK$19.7 million for the year ended 30 June 2024. The Board believes the Group's significant improvement in the financial results during the Reporting Period was mainly attributable to the net effect of, among other things, (i) the year-on-year increase in gross profit amounted to approximately HK$9.2 million or 184% due to business improvement; (ii) strengthened cost control on administrative and operating expenses; (iii) gain on loan capitalisation in the amount of approximately HK$3.9 million during the Reporting Period; and (iv) decrease in finance costs as a result of the loan capitalization during the Reporting Period.

As at the date of this announcement, the Company is still in the course of preparing and finalising its annual results of the Group for the Reporting Period. The information contained herein constitutes a preliminary assessment made by the Board based on currently available information, including the Group's unaudited consolidated financial statements for the Reporting Period. These financial statements have not been reviewed or audited by the Company's auditors nor reviewed by the audit committee of the Company. The actual annual results of the Group for the Reporting

Period may be subject to adjustment based on further updated information and may differ from the information disclosed herein. The shareholders and potential investors of the Company shall refer to the preliminary announcement of the annual results of the Group for the Reporting Period, which is expected to be published on or around 26 September 2025.

The shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Sinopharm Tech Holdings Limited
國藥科技股份有限公司
CHIU Sin Nang Kenny
Executive Director

Hong Kong, 22 September 2025

As at the date of this announcement, the Board comprises Mr. CHIU Sin Nang Kenny and Ms. KWOK Shuk Yi as executive Directors, Dr. CHENG Yanjie as non-executive Director and Mr. LAU Fai Lawrence, Mr. HSU Dong An and Mr. HEUNG Pik Lun as independent non-executive Directors.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the "Latest Listed Company Information" page of the website of The Stock Exchange of Hong Kong Limited at https://www.hkexnews.hk for a minimum period of 7 days from the date of its publication and on the website of the Company at http://www.sinopharmtech.com.hk.